公开(公告)号：US07201720B2

公开(公告)日：2007-04-10

申请号：US10400688

申请日：2003-03-28

Applicant: Oscar Cuzzani ,  Andrew J Barker ,  Donald E. James

Inventor： Oscar Cuzzani ,  Andrew J Barker ,  Donald E. James

IPC: A61B3/16

CPC classification number: A61B3/165 ,  A61B3/1005

Abstract: Apparatus and method for measuring Internal Ocular Pressure (IOP) comprises applying a perturbing vibration into an eye over a range of frequencies. A vibrational response of the surface of the eye is measured such as by using a laser velocimeter, the vibrational response including velocity and rate of change of the phase lag. Further, geometric properties such as volume of the eye are measured such as by using a laser interferometer to measure characteristics such as the eye's axial length and cornea thickness. Use of multiple characteristics normalizes the effect of an eye's mechanical and geometric properties and thereby more accurately determines the IOP.

Abstract translation: 用于测量内眼压（IOP）的装置和方法包括在一定范围的频率上对眼睛施加扰动振动。 测量眼睛表面的振动响应，例如通过使用激光测速仪，振动响应包括速度和相位滞后变化率。 此外，例如通过使用激光干涉仪来测量诸如眼睛的体积的几何特性来测量眼睛的轴向长度和角膜厚度等特征。 多重特征的使用使眼睛的机械和几何特性的效果正常化，从而更准确地确定眼压。

公开(公告)号：US06456596B2

公开(公告)日：2002-09-24

申请号：US09281138

申请日：1999-03-29

Applicant: Andrew J Barker

Inventor： Andrew J Barker

IPC: H04J316

CPC classification number: H04J3/08 ,  H04J2203/0025 ,  H04J2203/0042 ,  H04J2203/0053 ,  H04J2203/006 ,  H04J2203/0067

Abstract: In a digital telecommunications system having data packages carrying identification data, the identification data is characterized in that it is unique to the package within a station and does not depend on the identity of the originating station.

Abstract translation: 在具有携带识别数据的数据包的数字电信系统中，识别数据的特征在于它对于站内的包装是唯一的，并且不依赖于始发站的身份。

公开(公告)号：US5089499A

公开(公告)日：1992-02-18

申请号：US450670

申请日：1989-12-14

Applicant: Andrew J. Barker ,  Leslie R. Hughes ,  Peter R. Marsham ,  John Oldfield ,  Stephen J. Pegg

Inventor： Andrew J. Barker ,  Leslie R. Hughes ,  Peter R. Marsham ,  John Oldfield ,  Stephen J. Pegg

IPC: A61K31/505 ,  A61K31/517 ,  A61P35/00 ,  C07D20060101 ,  C07D239/90 ,  C07D239/95 ,  C07D239/96 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

CPC classification number: C07D401/12 ,  C07D239/90 ,  C07D239/95 ,  C07D239/96 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumor activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula: ##STR1## wherein R.sup.1 is hydrogen or amino, or alkyl or alkoxy each of up to 6 carbon atoms; or R.sup.1 is substituted alkyl or alkoxy each of up to 3 carbon atoms;R.sup.2 is hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, halogenoalkyl or cyanoalkyl each of up to 6 carbon atoms;Ar is phenylene or heterocyclene;L is a group of the formula --CO.NH--, --NH.CO--, --CO.NR.sup.3 --, --NR.sup.3. CO--, --CH.dbd.CH--, --CH.sub.2 O--, --OCH.sub.2, --CH.sub.2 S--, --SCH.sub.2 --, --CO.CH.sub.2 --, --CH.sub.2.CO-- or --CO.O--, wherein R.sup.3 is alkyl of up to 6 carbon atoms; andY is aryl or heteroaryl or a hydrogenated derivative thereof: orY is a group of the formula --A--Y.sup.1 in which A is alkylene, cycloalkylene, alkenylene or alkynylene each of up to 6 carbon atoms and Y.sup.1 is aryl or heteroaryl or a hydrogenated derivative thereof;or a pharmaceutically-acceptable salt thereof.

公开(公告)号：US4795748A

公开(公告)日：1989-01-03

申请号：US749384

申请日：1985-06-27

Applicant: Barry C. Ross ,  Michael D. Cooke ,  Nicholas I. Carruthers ,  Andrew J. Barker

Inventor： Barry C. Ross ,  Michael D. Cooke ,  Nicholas I. Carruthers ,  Andrew J. Barker

IPC: A61K31/397 ,  A61K31/425 ,  A61P31/04 ,  C07C69/90 ,  C07D205/08 ,  C07D205/09 ,  C07D499/88 ,  C07D499/897 ,  C07F7/18 ,  C07D499/00

CPC classification number: C07C69/90 ,  C07D205/08 ,  C07D205/09 ,  C07D499/88 ,  C07F7/186 ,  C07F7/1896

Abstract: A compound of the formula I ##STR1## in which R.sup.1 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, the --CONHR.sup.1 group being present at the 3- or 4-position on the phenyl ring, and esters thereof at the 2-carboxyl group and/or at the 8-hydroxy group, have antibacterial and/or .beta.-lactamase inhibiting activity.

Abstract translation: 其中R 1表示氢原子或具有1至4个碳原子的烷基的式I化合物（I），-CONHR 1基团存在于苯环上的3-或4-位， 及其在2-羧基和/或8-羟基的酯具有抑制和/或β-内酰胺酶抑制活性。

公开(公告)号：US06291507B1

公开(公告)日：2001-09-18

申请号：US09626241

申请日：2000-07-26

Applicant: Alan W Faull ,  Andrew J Barker ,  Jason G Kettle

Inventor： Alan W Faull ,  Andrew J Barker ,  Jason G Kettle

IPC: A61K3140

CPC classification number: C07D209/52 ,  A61K31/403 ,  C07D209/42

Abstract: A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt, ester or amide thereof, which is an inhibitor of monocyte chemoattractant protein-1, and wherein A and B form an optionally substituted alkylene chain so as to form a ring with the carbon atoms to which they are attached; X is CH2 or SO2, R1 is an optionally substituted aryl or heteroaryl ring; R2 is a specified organic group such as carboxy, and R3 is hydrogen or a specified organic group; in combination with a pharmaceutically acceptable carrier. Certain compounds of formula (I) are novel and are claimed as such.

Abstract translation: 一种药物组合物，其包含式（I）化合物或其药学上可接受的盐，酯或酰胺，其为单核细胞趋化蛋白-1的抑制剂，并且其中A和B形成任选取代的亚烷基链，以形成 与它们所连接的碳原子环; X是CH 2或SO 2，R 1是任选取代的芳基或杂芳基环; R2是指定的有机基团，例如羧基，R 3是氢或指定的有机基团; 与药学上可接受的载体组合。 某些式（I）的化合物是新颖的，并且是要求保护的。

公开(公告)号：US5457105A

公开(公告)日：1995-10-10

申请号：US284293

申请日：1994-08-02

Applicant: Andrew J. Barker

Inventor： Andrew J. Barker

IPC: A61K31/505 ,  A61K31/517 ,  A61P35/00 ,  C07D239/00 ,  C07D239/94 ,  C07D317/00 ,  C07D319/00 ,  C07D403/04 ,  C07D403/12 ,  C07D491/04 ,  C07D491/056 ,  A61K31/51 ,  A61K31/535 ,  C07D239/74 ,  C07D239/82

CPC classification number: C07D403/04 ,  C07D239/94 ,  C07D491/04

Abstract: The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R.sup.1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy;n is 1 or 2 and each R.sup.2 includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl;or a pharmaceutically-acceptable salt thereof;processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.

Abstract translation: 本发明涉及式I的喹唑啉衍生物，其中m为1,2或3，并且每个R 1包括羟基，氨基，羧基，氨基甲酰基，脲基，（1-4C）烷氧基羰基，N-（1-4C）烷基氨基甲酰基 N，N-二 - [（1-4C）烷基]氨基甲酰基，羟基氨基，（1-4C）烷氧基氨基，（2-4C）烷酰氧基氨基，三氟甲氧基，（1-4C）烷基，（1-4C）烷氧基和（ 1-3C）亚烷基二氧基; n为1或2，每个R2包括氢，羟基，卤代，三氟甲基，氨基，硝基，氰基和（1-4C）烷基; 或其药学上可接受的盐; 其准备过程; 含有它们的药物组合物; 以及使用受体酪氨酸激酶抑制化合物治疗癌症的性质。

公开(公告)号：US5280027A

公开(公告)日：1994-01-18

申请号：US708046

申请日：1991-05-30

Applicant: Robert G. Andrew ,  Andrew J. Barker ,  Francis T. Boyle ,  James M. Wardleworth

Inventor： Robert G. Andrew ,  Andrew J. Barker ,  Francis T. Boyle ,  James M. Wardleworth

IPC: A61K31/505 ,  A61K31/517 ,  A61P35/00 ,  C07D239/88 ,  C07D239/90 ,  C07D239/95 ,  C07D239/96 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D403/12 ,  C07D239/90 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity; to processes for their manufacture; and to pharmaceutical compositions containing them.The invention provides a quinazoline of the formula: ##STR1## wherein R.sup.1 includes hydrogen, amino and alkyl or alkoxy each of up to 4 carbon atoms;R.sup.2 includes hydrogen, alkyl, hydroxyalkyl and halogenoalkyl each of up to 4 carbon atoms;R.sup.3 is hydrogen or alkyl or up to 3 carbon atoms;Ar is phenylene or heterocyclene;L is a group of the formula --CO.NH--, --NH.CO--, --CO.NR.sup.4 --, --NR.sup.4.CO--, --CH.dbd.CH-- or --CO.O--, wherein R.sup.4 is alkyl of up to 4 carbon atoms; and Y is a branched alkyl group bearing substituents Y.sup.2 and Y.sup.3 the definition of each independently including hydroxy, cyano, aryl and heteroaryl, and the definition of Y.sup.3 also optionally including sulpho, N-phenylsulphonylcarbamoyl and 5-tetrazolyl; or a pharmaceutically-acceptable salt thereof.

Abstract translation: 本发明涉及具有抗肿瘤活性的喹唑啉衍生物或其药学上可接受的盐; 制造过程; 以及含有它们的药物组合物。 本发明提供下式的喹唑啉：（*化学结构*）其中R1包括氢，氨基和至多4个碳原子的烷基或烷氧基; R2包括至多4个碳原子的氢，烷基，羟基烷基和卤代烷基; R3是氢或烷基或至多3个碳原子; Ar是亚苯基或杂环烯; L是式-CO.NH-，-NH.CO-，-CO.NR4-，-NR4CO-，-CH = CH-或-CO.O-的基团，其中R4是直至 4个碳原子; Y是带有取代基Y2和Y3的支链烷基，其各自独立地包括羟基，氰基，芳基和杂芳基，Y 3的定义也任选地包括磺基，N-苯基磺酰基氨基甲酰基和5-四唑基; 或其药学上可接受的盐。

公开(公告)号：US4455086A

公开(公告)日：1984-06-19

申请号：US347132

申请日：1982-02-09

Applicant: Robert N. West ,  Andrew J. Barker

Inventor： Robert N. West ,  Andrew J. Barker

IPC: G01N21/89 ,  G01N21/00

CPC classification number: G01N21/8901

Abstract: Test apparatus and method for testing for faults in, for example, transparent sheet material in which two parallel beams of light separated by a distance "w" are passed through a grating having, for example, light transmitting and absorbing areas separated by a distance "w", so that as the two beams are scanned across the object and the grating the light output through the grating is generally constant. If, however, there are faults which displace one beam with respect to the other, then the spacing between the beams will change so the light output will vary from the norm. Furthermore, if there is a fault which would cause attenuation of the two beams, then the light output will again vary from the norm.

Abstract translation: 用于测试例如透明片材的测试装置和方法，其中将两个平行光束分开一段距离“w”的光束通过光栅，该光栅具有例如隔开距离“ w“，使得当两个光束跨过物体和光栅扫描时，通过光栅输出的光通常是恒定的。 然而，如果存在相对于另一个移动一个光束的故障，则光束之间的间隔将改变，使得光输出将随规范变化。 此外，如果存在将导致两个光束衰减的故障，则光输出将再次从标准变化。

公开(公告)号：US06513136B1

公开(公告)日：2003-01-28

申请号：US09432317

申请日：1999-11-02

Applicant: Andrew J. Barker

Inventor： Andrew J. Barker

IPC: G06F1100

CPC classification number: H04L25/063 ,  H04L1/0045 ,  H04L1/0057

Abstract: A receiver in a digital communications system, in which the digital data occupy a number of levels, equalises the erroneous-count rates for the various data levels by deriving the count rates for the levels, comparing these count rates with each other and using the comparison result to adjust the threshold level which is used to detect the received data train. The error-counts are preferably derived as a byproduct of a Forward Error Correction system already available for performing normal error correction on the received data. The receiver arrangement is envisaged to find predominant application in a two-level system involving logical “1”'s and “0”'s, though it is applicable also to systems with three or more levels.

Abstract translation: 在数字通信系统中的数字数据占用多个级别的接收机，通过导出电平的计数率，将这些计数率相互比较并使用比较来均衡各种数据电平的错误计数率 结果调整用于检测接收到的数据序列的阈值水平。 错误计数优选地被导出为已经可用于对所接收的数据执行正常纠错的前向纠错系统的副产品。 接收机布置被设想在涉及逻辑“1”和“0”的两级系统中找到主要应用，尽管它也适用于具有三个或更多个级别的系统。

公开(公告)号：US06479527B1

公开(公告)日：2002-11-12

申请号：US09626378

申请日：2000-07-26

Applicant: Andrew J. Barker ,  Alan W Faull ,  Jason G. Kettle

Inventor： Andrew J. Barker ,  Alan W Faull ,  Jason G. Kettle

IPC: A61K31407

CPC classification number: C07D487/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: A pharmaceutical composition comprising a compound of formula (I): or a pharmaceutically acceptable salt, ester or amide thereof, which is an inhibitor of monocyte chemoattractant protein-1 and wherein A and B together form an optionally substituted 5-member aromatic ring which includes at least one heteroatom; R1 is an optionally substituted aryl or heteroaryl ring; R2 is selected from a range of organic groups including carboxy, and R3 is hydrogen, or a range of organic groups; in combination with a pharmaceutically acceptable carrier. Certain compounds of formula (I) are novel and these form a further aspect of the invention.

Abstract translation: 一种药物组合物，其包含式（I）化合物或其药学上可接受的盐，酯或酰胺，其为单核细胞趋化蛋白-1的抑制剂，其中A和B一起形成任选取代的5元芳环，其包括 至少一个杂原子; R1是任选取代的芳基或杂芳基环; R2选自一系列有机基团，包括羧基，R3是氢或一定范围的有机基团; 与药学上可接受的载体组合。 某些式（I）化合物是新的，这些是本发明的另一方面。